北京伯汇生物技术

Bohui Biotech is a clinical-stage biopharmaceutical company headquartered in Beijing, China, focused on the discovery and development of innovative multi-specific antibody therapeutics for cancer treatment. The company leverages its proprietary B-Body™ platform, which enables the rapid generation of bispecific and multi-specific antibodies with high stability and drug-like properties. Its lead clinical candidate, BH3120, is a bispecific antibody targeting 4-1BB and PD-L1, designed to activate the immune system specifically within the tumor microenvironment. By focusing on next-generation immunotherapies, Bohui Biotech aims to address unmet medical needs in patients with advanced solid tumors. The company maintains strategic collaborations, including a significant partnership with Hansoh Pharma for the development and commercialization of its lead assets.